Understanding the Market | EVEREST MED rises over 5% against the market trend as Nanfukang receives full approval in China, validating the company's commercialization capabilities
EVEREST MED rose over 5% against the market trend, and as of the time of writing, it is up 4.49%, trading at HKD 46.5, with a transaction volume of HKD 144 million. In terms of news, EVEREST MED previously announced that Naifukang (Budesonide enteric-coated capsules) has officially received approval from the National Medical Products Administration (NMPA) to transition from conditional approval to full approval for the treatment of adult patients with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression, aimed at reducing kidney function loss. The new indication solidifies Naifukang's position as a first-line cornerstone treatment for IgA nephropathy, and this full approval means that the complete data from Naifukang's clinical research has been validated, making it the first and only IgA nephropathy etiology treatment drug to receive full approval from the NMPA in China. Notably, on April 22, EVEREST MED received formal approval from the Stock Exchange to remove the "B" mark from its stock code, marking an important milestone in EVEREST MED's transition to a "commercially mature enterprise," indicating that it has reached higher standards in terms of market capitalization and revenue, with its commercialization capabilities further recognized
According to Zhitong Finance APP, Everest Med (01952) rose more than 5% against the market trend, and as of the time of writing, it was up 4.49%, trading at HKD 46.5, with a transaction volume of HKD 144 million.
In terms of news, Everest Med previously announced that Naifukang (Budesonide enteric-coated capsules) has officially received approval from the National Medical Products Administration (NMPA) to transition from conditional approval to full approval for the treatment of adult patients with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression, aimed at reducing kidney function loss. The new indication solidifies Naifukang's position as a first-line cornerstone treatment for IgA nephropathy, and this full approval means that the complete data from Naifukang's clinical research has been validated, making it the first and only IgA nephropathy causal treatment drug to receive full approval from the NMPA in China.
It is worth noting that on April 22, Everest Med received formal approval from the Stock Exchange to remove the "B" mark from its stock code, marking an important milestone in its transition to a "commercially mature enterprise," indicating that Everest Med has reached higher standards in terms of market capitalization and revenue, with its commercialization capabilities further recognized
